Biotechnology News and Research

RSS

AgenoLAB acquires Roche´s RTCA Cardio Instrument

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA Cardio Instrument to complement their analytical service portfolio for drug development.

13 May 2011

Reaxys, Syngene sign multi-year contract to enhance R&D competitiveness and productivity

Elsevier, the world's leading publisher of scientific content and online solutions announced today that Syngene, India's first contract research organization, has signed a multi-year contract that will provide unlimited access to Reaxys for all Syngene researchers.

13 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

Cancer studies from Mercer University headline groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC).

13 May 2011

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, presented new clinical and pre-clinical data related to the safety and efficacy of its novel, lead defensin-mimetic antibiotic, PMX-30063.

12 May 2011

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction platform.

12 May 2011

Miltenyi Biotec enters partnership with TeutoCell to develop novel cell culture techniques

Miltenyi Biotec, the only company to offer a seamless experimental integration path from sample preparation through cell separation, culture, and analysis for primary cells, today entered into a strategic alliance with TeutoCell, a provider of cutting edge cell culture technology.

12 May 2011

Cell Biosciences announces acquisition of Brightwell Technologies

Cell Biosciences, Inc. today announced that it has acquired Brightwell Technologies, Inc. of Ottawa, Ontario for approximately U.S. $9 million in cash.

12 May 2011

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

12 May 2011

Salmonella enterica bacterium activates virulence genes through Fur protein

Salmonella enterica, one of the main causes of gastrointestinal infections, modulates its virulence gene expression, adapting it to each stage of the infection process, depending on the free iron concentration found in the intestinal epithelium of its host.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

China Pharma first quarter revenue increases 20% to $18.1 million

China Pharma Holdings, Inc., a fully-integrated specialty pharmaceuticals company in China, today announced financial results for the quarter ended March 31, 2011.

11 May 2011

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Oncolytics Biotech Inc. today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus.

11 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

ICON partners with BCRI for clinical research

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced a strategic alliance with Boston Clinical Research Institute, an Academic Research Organisation based in Boston, Massachusetts.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis.

11 May 2011

MTTI obtains exclusive license for novel fluorescence dyes from Massachusetts General Hospital

Molecular Targeting Technologies, Inc., announced that it has obtained an exclusive license from the Massachusetts General Hospital for novel fluorescence dyes developed by Scott Hilderbrand, Ph.D. Fangwei Shao, Ph.D., and Ralph Weissleder, Ph.D. M.D.

11 May 2011

Biotechnology News and Research

AgenoLAB acquires Roche´s RTCA Cardio Instrument

Reaxys, Syngene sign multi-year contract to enhance R&D competitiveness and productivity

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Groundbreaking cancer treatment studies to be unveiled at AAPS National Biotechnology Conference

New clinical data affirms safety profile of PolyMedix's PMX-30063 in treatment of Staph infections

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Miltenyi Biotec enters partnership with TeutoCell to develop novel cell culture techniques

Cell Biosciences announces acquisition of Brightwell Technologies

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Salmonella enterica bacterium activates virulence genes through Fur protein

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

China Pharma first quarter revenue increases 20% to $18.1 million

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Symphogen to present second-generation Sympress platform at ESACT conference

Naurex announces completion of $18 million Series A financing

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

ICON partners with BCRI for clinical research

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

16-year-old uses supercomputing network to invent new drug cocktail for cystic fibrosis

MTTI obtains exclusive license for novel fluorescence dyes from Massachusetts General Hospital

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News